Development and Validation of the FBIndex to Determine the Risk of Falls for Patients with Neuromuscular Disorders
Launched by LMU KLINIKUM · Sep 18, 2024
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The NMD people are characterised by a complex muscle weakness caused by a combination of different factors. These include reduced endurance, lack of explosive muscle force and power, intramuscular strength coordination, and reduced balance. Those parameters need to be considered when developing an appropriate fall risk score. The combination of short muscular function and balance assessments with short clinical scores, can be a new, valid approach to evaluating the patient's risk of falling. In addition, it assists in creating a quick checkup for prescribing an appropriate assistive device....
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Only patients with adequate cognitive and communicative function to give informed consent and to fill out the scale assessing the risk of falling will be included.
- Exclusion Criteria:
- • Patients who are unable to walk without AGD for at least 10 meters.
- • Patients who had knee, hip or back surgery in the last three months.
- • Patients who suffer from polyneuropathy or peripheral neuropathy.
About Lmu Klinikum
LMU Klinikum is a leading academic medical center affiliated with Ludwig Maximilian University in Munich, Germany. Renowned for its commitment to innovative research and high-quality patient care, LMU Klinikum plays a pivotal role in advancing medical science through clinical trials and translational research. With a multidisciplinary approach, the institution collaborates with various stakeholders, including healthcare professionals, researchers, and industry partners, to facilitate groundbreaking studies that aim to improve therapeutic outcomes and enhance understanding of complex diseases. Its state-of-the-art facilities and expert clinical teams ensure the highest standards of safety and efficacy in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
München, Bavaria, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported